I MAB【IMAB】株式ニュース | ADVFN

US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

I MAB (IMAB)

0.83995

0.00035

(0.04%)

終了 3月15日 5:00AM

0.83995

0.00

(0.00%)

取引時間後: 8:50AM

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member

I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member PR...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical...

I-Mab to Participate at the Piper Sandler Healthcare Conference

I-Mab to Participate at the Piper Sandler Healthcare Conference PR Newswire ROCKVILLE, Md., Nov. 21, 2024 The...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab Reports Third Quarter 2024 Results

I-Mab Reports Third Quarter 2024 Results PR Newswire ROCKVILLE, Md., Nov. 14, 2024 Givastomig data presented...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer PR Newswire ROCKVILLE, Md., Nov. 6, 2024...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

glenn1919

glenn1919 5月前

IMAB.......................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 5月前

IMAB.................................https://stockcharts.com/h-sc/ui?s=IMAB&p=W&b=5&g=0&id=p86431144783

Monksdream

Monksdream 6月前

Monksdream

Monksdream 8月前

Monksdream

Monksdream 8月前

stock1ace1

stock1ace1 10月前

Imab $1.80 golden cross https://schrts.co/CNBigxhc

I-Mab Price Target Maintained With a $6.00/Share by Needham
Mentioned: IMAB

Ratings actions from Benzinga: https://www.benzinga.com/quote/IMAB/analyst-ratings

(END) Dow Jones Newswires

April 12, 2024 06:15 ET (10:15 GMT)

Monksdream

Monksdream 11月前

IMAB 10Q due 4/3

Monksdream

Monksdream 12月前

Monksdream

Monksdream 12月前

Monksdream

Monksdream 1年前

AGORDON

AGORDON 1年前

IMAB
This is a long-term deal. The China divestiture had to be done to facilitate the future sale of the company. There would be too many Chinese entities to satisfy and hence introduce uncertainty in a future sale. The loss of the Jumpcan deal is a negative because the numbers were spelled out. I will feel much more comfortable about IMAB after they get a Giva or a Uli licensing deal. Combined, based on prior deals for similar drugs would be worth $1B+. It is likely they will have to pay out $30M to the non participants. The $80M from Hangzhou will take years to collect. But, there is one point that has not been addressed. That is the pricing of drugs in China. The Chinese government is notorious for asking for discounts. The pricing of drugs in the USA is better. IMAB has shifted its focus to drugs in a market where they will get much better pricing. The unknown is will IMAB get a deal for Giva, or Uli ?

AGORDON

AGORDON 1年前

2-3 minutes before the close over 500k shares were dumped. Same exercise happened to several Chinese stocks.

AGORDON

AGORDON 1年前

Based on the Astra Zeneca agreement with KYM for their Claudin 18.2 drug, and the Antengene agreement with Calithera for their CD73 inhibitor drug, I estimate that IMAB has potential contracts worth $1.25B+.

AGORDON

AGORDON 1年前

Why doesn't IMAB license Givasgtomig and Ulilidimab? I estimate that the milestone payments would be at least $500M. The share would be at least $5.

AGORDON

AGORDON 1年前

From the 20-F report

On July 16, 2022, I-Mab Hangzhou entered into a definitive financing agreement with a group of domestic investors in China to raise approximately US$46 million (in RMB equivalent). On the same date, we, through our wholly-owned subsidiary, entered into a shareholders agreement with I-Mab Hangzhou and other domestic investors in I-Mab Hangzhou named therein (the “I-Mab Hangzhou Shareholders Agreement”). Upon the occurrence of certain triggering events as specified in the I-Mab Hangzhou Shareholders Agreement, including but not limited to I-Mab Hangzhou’s failure to accomplish certain public offering condition, we may be obligated to repurchase the equity held by other domestic investors in cash or in our stocks in the period beyond 12 months.

AGORDON

AGORDON 1年前

In the most recent reporting period, Decheng Capital purchased 4 million shares of IMAB.

AGORDON

AGORDON 1年前

The stock has bounced off $1.80 two times within a month.

AGORDON

AGORDON 1年前

Not a surprise to see a pull back from the +50% rise last week. A large order came in at the end of yesterday. Nevertheless, it is disappointing to see the slide. It could fall back to $1.28. Mr. Kannan will be at a conference on 11/14. I think the China approvals will send the stock past $3 next year. The company will be sold by the end of 2025.

Mt. Blanc

Mt. Blanc 1年前

IMAB climbing the charts tracking the $3s. Check it out soon.

mb

Monksdream

Monksdream 1年前

Catering International &...

Republic Holding Ad

Granite 3s Ftng

Parker Drilling

Pioneer Municipal High I...

Jpmorgan European Growth...

DAXglobal Gold Miners In...

Inter Amerra Fiagro Imob...

ETFS 1x Daily Short Bren...

SPDR MSCI World Strategi...

Invl Technology Ab

Podium Minerals

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約